Intranasal delivery-Modification of drug metabolism and brain disposition

Pharmaceutical Research

Volumn 27, Issue 7, 2010, Pages 1208-1223

  Wong, Yin Cheong ^a   Zuo, Zhong ^a  

^a and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

Author keywords

Active metabolite; Brain distribution; Central nervous system; Drug delivery; Intranasal; Metabolism

Indexed keywords

BECLOMETASONE DIPROPIONATE; BENZOYLECGONINE; BUTORPHANOL; CHARCOAL; CHITOSAN; CICLESONIDE; COCAINE; CORTICOSTEROID; CYTOCHROME; DESMOPRESSIN; DIAMORPHINE; DIAZEPAM; DRUG METABOLITE; GLYCOPROTEIN P INHIBITOR; HOMOCOCAINE; LEUCINE ENKEPHALIN; LEVODOPA; MORPHINE; MORPHINE 3 GLUCURONIDE; MORPHINE 6 GLUCURONIDE; NIPECOTIC ACID; NORZOLMITRIPTAN; OPIATE DERIVATIVE; OXAZEPAM; PROTEINASE INHIBITOR; ZOLMITRIPTAN;

AREA UNDER THE CURVE; BLOOD BRAIN BARRIER; BRAIN; CEREBROSPINAL FLUID; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG HALF LIFE; DRUG METABOLISM; DRUG TARGETING; DRUG TRANSPORT; ENZYMATIC DEGRADATION; ENZYME ACTIVITY; FIRST PASS EFFECT; GASTROINTESTINAL TRACT; HUMAN; HYDROPHILICITY; INTESTINE ABSORPTION; INTRANASAL DRUG ADMINISTRATION; LIPOPHILICITY; LIVER METABOLISM; MIGRAINE; NONHUMAN; NOSE CAVITY; NOTE; PRIORITY JOURNAL; METABOLISM;

ADMINISTRATION, INTRANASAL; BRAIN; DRUG DELIVERY SYSTEMS; HUMANS; NASAL CAVITY;

EID: 77953617658     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-010-0127-5     Document Type: Note

References (125)

1. A Fura Y Shu M Zhu RL Hanson V Roongta WG Humphreys 2004 Discovering drugs through biological transformation: role of pharmacologically active metabolites in drug discovery J Med Chem. 47 4339 4351 1:CAS:528: DC%2BD2cXmtVejsbs%3D 15317447
2. AR Dahl WM Hadley 1991 Nasal cavity enzymes involved in xenobiotic metabolism: effects on the toxicity of inhalants Crit Rev Toxicol 21 345 372 1:CAS:528:DyaK3MXmtVSnsrc%3D 1741949
3. Ding X, Dahl AR. Olfactory mucosa: composition, enzymatic localization, and metabolism. In: Doty RL, editor, Handbook of Olfaction and Gustation. New York: Marcel Dekker; 2003. p. 51-74.
4. JB Morris AR Buckpitt 2009 Upper respiratory tract uptake of naphthalene Toxicol Sci. 111 383 391 1:CAS:528:DC%2BD1MXhtFaku7bP 19648534
5. PG Gervasi V Longo F Naldi G Panattoni F Ursino 1991 Xenobiotic- metabolizing enzymes in human respiratory nasal mucosa Biochem Pharmacol 41 177 184 1:CAS:528:DyaK3MXps1Crug%3D%3D 1989628
6. V Longo GM Pacifici G Panattoni F Ursino PG Gervasi 1989 Metabolism of diethylnitrosamine by microsomes of human respiratory nasal mucosa and liver Biochem Pharmacol 38 1867 1869 1:CAS:528:DyaL1MXktlGjsrg%3D 2735943
7. Rahmel D. Investigations of gene expression and metabolic activity of the human respiratory nasal mucosa. Hannover, Tierärztliche Hochschule, Dissertation, 2004.
8. A Minn H Pelczar C Denizot M Martinet J Heydel B Walther A Minn H Goudonnet Y Artur 2005 Characterization of microsomal cytochrome P450-dependent monooxygenases in the rat olfactory mucosa Drug Metab Dispos 33 1229 1237 1:CAS:528:DC%2BD2MXntVamsb8%3D 15879494
9. A Minn S Leclerc J Heydel A Minn C Denizot M Cattarelli P Netter D Gradinaru 2002 Drug transport into the mammalian brain: the nasal pathway and its specific metabolic barrier J Drug Target. 10 285 296 1:CAS:528: DC%2BD38XktlCrt7g%3D 12164377
10. JR Thornton-Manning AR Dahl 1997 Metabolic capacity of nasal tissue. Interspecies comparisons of xenobiotic-metabolizing enzymes Mutat Res 380 43 59 1:CAS:528:DyaK2sXmsVKrsLw%3D 9385389
11. CJ Reed 1993 Drug metabolism in the nasal cavity: relevance to toxicology Drug Metab Rev 25 173 205 1:CAS:528:DyaK3sXktVSju74%3D 8449146
12. FWHM Merkus MP van den Berg 2007 Can nasal drug delivery bypass the blood-brain barrier? Questioning the direct transport theory Drugs R. 8 133 144 1:CAS:528:DC%2BD2sXntVSnsrw%3D
13. L Illum 2003 Nasal drug delivery-possibilities, problems and solutions J Controlled Release. 87 187 198 1:CAS:528:DC%2BD3sXhsFOls7c%3D
14. H Sato R Nave T Nonaka T Mochizuki S Takahama S Kondo 2007 In vitro metabolism of ciclesonide in human nasal epithelial cells Biopharm Drug Dispos 28 43 50 1:CAS:528:DC%2BD2sXhtFCmu7o%3D 17117454
15. R Nave N McCracken 2008 Metabolism of ciclesonide in the upper and lower airways: review of available data J Asthma Allergy. 1 11 18 1:CAS:528: DC%2BD1cXhsFSnsrbF
16. SD Kashi VHL Lee 1986 Enkephalin hydrolysis in homogenates of various absorptive mucosae of the albino rabbit: similarities in rates and involvement of aminopeptidases Life Sci 38 2019 2028 1:CAS:528:DyaL28XktFyrtbY%3D 3713436
17. E Krondahl A Tronde S Eirefelt H Forsmo-Bruce G Ekstrom U Hultkvist Bengtsson H Lennernas 2002 Regional differences in bioavailability of an opioid tetrapeptide in vivo in rats after administration to the respiratory tract Peptides 23 479 488 1:CAS:528:DC%2BD38XhtVKrsLs%3D 11835997
18. K Ohkubo JN Baraniuk R Hohman M Merida LB Hersh MA Kaliner 1998 Aminopeptidase activity in human nasal mucosa J Allergy Clin Immunol. 102 741 750 1:CAS:528:DyaK1cXotVehs7w%3D 9819290
19. VD Hoang AR Uchenna J Mark K Renaat V Norbert 2002 Characterization of human nasal primary culture systems to investigate peptide metabolism Int J Pharm. 238 247 256 1:CAS:528:DC%2BD38XjtlGht7c%3D 11996828
20. XH Zhou ALW Po 1991 Comparison of enzyme activities of tissues lining portals of absorption of drugs: species differences Int J Pharm. 70 271 283 1:CAS:528:DyaK3MXit1Sksbg%3D
21. K Jonsson K Alfredsson C Soderberg-Ahlm H Critchley A Broders M Ohlin 1992 Evaluation of the degradation of desamino1, D-arginine8-vasopressin by nasal mucosa Acta Endocrinol. 127 27 32 1:CAS:528:DyaK38XmtVGntLk%3D 1519419
22. S Lundin HI Bengtsson HG Folkesson BR Westroem 1989 Degradation of [mercaptopropionic acid1, D-arginine8]-vasopressin (dDAVP) in pancreatic juice and intestinal mucosa homogenate Pharmacol Toxicol 65 92 95 1:CAS:528: DyaL1MXls1Oltbw%3D 2813288
23. MS Bogdanffy LA Manning R Sarangapani 1999 High-affinity nasal extraction of vinyl acetate vapor is carboxylesterase dependent Inhalation Toxicol. 11 927 941 1:CAS:528:DyaK1MXnt1Gksbo%3D
24. JA Faraj AA Hussain Y Aramaki K Iseki M Kagoshima LW Dittert 1990 Mechanism of nasal absorption of drugs. III: nasal absorption of leucine enkephalin J Pharm Sci. 79 698 702 1:CAS:528:DyaK3cXmtFOqurc%3D 2231332
25. M Christiane Schmidt W Rubas HP Merkle 2000 Nasal epithelial permeation of thymotrinan (TP3) versus thymocartin (TP4): competitive metabolism and self-enhancement Pharm Res 17 222 228 1:CAS:528:DC%2BD3cXitVOqurY%3D
26. E Marttin NGM Schipper JC Verhoef FWHM Merkus 1998 Nasal mucociliary clearance as a factor in nasal drug delivery Adv Drug Delivery Rev. 29 13 38 1:CAS:528:DyaK2sXnvFGgsL0%3D
27. K Fattinger NL Benowitz RT Jones D Verotta 2000 Nasal mucosal versus gastrointestinal absorption of nasally administered cocaine Eur J Clin Pharmacol 56 305 310 1:CAS:528:DC%2BD3cXkslWktb8%3D 10954344
28. M Kaagedal P-H Zingmark C Hedlund R Yates 2005 True nasopharyngeal absorption of zolmitriptan after administration via nasal spray in healthy male volunteers Am J Drug Delivery. 3 133 140 1:CAS:528:DC%2BD28Xhs1ais7s%3D
29. PT Daley-Yates AC Price JR Sisson A Pereira N Dallow 2001 Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man Br J Clin Pharmacol 51 400 409 1:CAS:528:DC%2BD3MXksFantL8%3D 11421996
30. T Furubayashi A Kamaguchi K Kawaharada Y Masaoka M Kataoka S Yamashita Y Higashi T Sakane 2007 Evaluation of the contribution of the nasal cavity and gastrointestinal tract to drug absorption following nasal application to rats Biol Pharm Bull 30 608 611 1:CAS:528:DC%2BD2sXkvVSnurY%3D 17329868
31. MI Ugwoke RU Agu N Verbeke R Kinget 2005 Nasal mucoadhesive drug delivery: background, applications, trends and future perspectives Adv Drug Delivery Rev. 57 1640 1665 1:CAS:528:DC%2BD2MXhtFSisL7N
32. AS Harris IM Nilsson ZG Wagner U Alkner 1986 Intranasal administration of peptides: nasal deposition, biological response, and absorption of desmopressin J Pharm Sci. 75 1085 1088 1:CAS:528:DyaL2sXmtFCqsA%3D%3D 3102719
33. AS Harris M Ohlin S Lethagen IM Nilsson 1988 Effects of concentration and volume on nasal bioavailability and biological response to desmopressin J Pharm Sci. 77 337 339 1:CAS:528:DyaL1cXitFSju7s%3D 3379594
34. JK Coller LL Christrup AA Somogyi 2009 Role of active metabolites in the use of opioids Eur J Clin Pharmacol 65 121 139 1:CAS:528:DC%2BD1MXhtVCksbY%3D 18958460
35. O Dale R Hjortkjaer ED Kharasch 2002 Nasal administration of opioids for pain management in adults Acta Anaesthesiol Scand 46 759 770 1:STN:280:DC%2BD38vktFSlug%3D%3D 12139528
36. K Shelley MJ Paech 2008 The clinical applications of intranasal opioids Curr Drug Delivery. 5 55 58 1:CAS:528:DC%2BD1cXktVegsA%3D%3D
37. EJ Rook ADR Huitema W van den Brink JM van Ree JH Beijnen 2006 Pharmacokinetics and pharmacokinetic variability of heroin and its metabolites: review of the literature Curr Clin Pharmacol. 1 109 118 1:CAS:528: DC%2BD28XitFOnsr0%3D 18666382
38. EJ Cone BA Holicky TM Grant WD Darwin BA Goldberger 1993 Pharmacokinetics and pharmacodynamics of intranasal "snorted" heroin J Anal Toxicol. 17 327 337 1:CAS:528:DyaK3sXms1agt7g%3D 8271778
39. G Skopp B Ganssmann EJ Cone R Aderjan 1997 Plasma concentrations of heroin and morphine-related metabolites after intranasal and intramuscular administration J Anal Toxicol. 21 105 111 1:CAS:528:DyaK2sXitVWksLc%3D 9083827
40. JM Kendall VS Latter 2003 Intranasal diamorphine as an alternative to intramuscular morphine: pharmacokinetic and pharmacodynamic aspects Clin Pharmacokinet 42 501 513 1:CAS:528:DC%2BD3sXmtVGmur0%3D 12793836
41. L Illum P Watts AN Fisher M Hinchcliffe H Norbury I Jabbal-Gill R Nankervis SS Davis 2002 Intranasal delivery of morphine J Pharmacol Exp Ther. 301 391 400 1:CAS:528:DC%2BD38Xis1KqsLg%3D 11907197
42. Dhuria SV, Hanson LR, Frey II WH. Intranasal delivery to the central nervous system: Mechanisms and experimental considerations. J Pharm Sci. 2009.
43. V Jogani K Jinturkar T Vyas A Misra 2008 Recent patents review on intranasal administration for CNS drug delivery Recent Pat Drug Deliv Formul 2 25 40 1:CAS:528:DC%2BD1cXhsVajsbg%3D 19075895
44. DS Dhanda WH Frey II D Leopold UB Kompella 2005 Approaches for drug deposition in the human olfactory epithelium Drug Delivery Technol 5 64 72 1:CAS:528:DC%2BD2MXktVOqtLk%3D
45. TK Vyas A Shahiwala S Marathe A Misra 2005 Intranasal drug delivery for brain targeting Curr Drug Delivery 2 165 175 1:CAS:528:DC%2BD2MXjtFajs7s%3D
46. L Illum 2000 Transport of drugs from the nasal cavity to the central nervous system Eur J Pharm Sci. 11 1 18 1:CAS:528:DC%2BD3cXksFektLo%3D 10913748
47. CL Graff R Zhao GM Pollack 2005 Pharmacokinetics of substrate uptake and distribution in murine brain after nasal instillation Pharm Res 22 235 244 1:CAS:528:DC%2BD2MXitlCltro%3D 15783071
48. H-S Chow Z Chen GT Matsuura 1999 Direct transport of cocaine from the nasal cavity to the brain following intranasal cocaine administration in rats J Pharm Sci. 88 754 758 1:CAS:528:DyaK1MXktFektL0%3D 10430537
49. H-S Chow N Anavy A Villalobos 2001 Direct nose-brain transport of benzoylecgonine following intranasal administration in rats J Pharm Sci. 90 1729 1735 1:CAS:528:DC%2BD3MXosVKltrs%3D 11745730
50. GJ Kilpatrick TW Smith 2005 Morphine-6-glucuronide: actions and mechanisms Med Res Rev 25 521 544 1:CAS:528:DC%2BD2MXhtVGiurfN 15952175
51. CC Faura SL Collins RA Moore HJ McQuay 1998 Systematic review of factors affecting the ratios of morphine and its major metabolites Pain 74 43 53 1:CAS:528:DyaK1cXivVSntQ%3D%3D 9514559
52. CL Graff GM Pollack 2003 P-glycoprotein attenuates brain uptake of substrates after nasal instillation Pharm Res 20 1225 1230 1:CAS:528: DC%2BD3sXmtVGrtb4%3D 12948020
53. CL Graff GM Pollack 2005 Functional evidence for P-glycoprotein at the nose-brain barrier Pharm Res 22 86 93 1:CAS:528:DC%2BD2MXhtlCksro%3D 15771234
54. F Marcucci A Guaitani J Kvetina E Mussini S Garattini 1968 Species difference in diazepam metabolism and anticonvulsant effect Eur J Pharmacol 4 467 470 1:CAS:528:DyaF1MXlsF2isw%3D%3D 5724923
55. F Marcucci E Mussini 1968 A metabolic explantation for differences between species of the anticonvulsant activity of diazepam Br J Pharmacol 34 667P 668P 1:STN:280:DyaF1M%2FmtlOhug%3D%3D 5726801
56. F Marcucci E Mussini R Fanelli S Garattini 1970 Species differences in diazepam metabolism. I. Metabolism of diazepam metabolites Biochem Pharmacol 19 1847 1851 1:CAS:528:DyaE3cXktlemtbs%3D 5513967
57. DJ Greenblatt BL Ehrenberg J Gunderman JM Scavone NT Tai JS Harmatz RI Shader 1989 Kinetic and dynamic study of intravenous lorazepam: comparison with intravenous diazepam J Pharmacol Exp Ther. 250 134 140 1:CAS:528: DyaL1MXkvFSgtro%3D 2746493
58. DJ Greenblatt VH Sethy 1990 Benzodiazepine concentrations in brain directly reflect receptor occupancy: studies of diazepam, lorazepam, and oxazepam Psychopharmacology (Berlin) 102 373 378 1:CAS:528:DyaK3cXmt1Cju7o%3D
59. P Kaur K Kim 2008 Pharmacokinetics and brain uptake of diazepam after intravenous and intranasal administration in rats and rabbits Int J Pharm. 364 27 35 1:CAS:528:DC%2BD1cXht1yktbvM 18760341
60. K Saito N Sakai H Kim M Ishizuka A Kazusaka S Fujita 2004 Strain differences in diazepam metabolism at its three metabolic sites in sprague-dawley, brown norway, dark agouti, and Wistar strain rats Drug Metab Dispos 32 959 965 1:CAS:528:DC%2BD2cXnsVegtLk%3D 15319337
61. H Kim N Sakai K Saito S Fujita M Ishizuka 2010 Diazepam metabolism in the kidneys of male and female rats of various strains J Vet Med Sci. 72 7 11 1:CAS:528:DC%2BC3cXis1WmtLk%3D 19893285
62. WZ Potter MV Rudorfer EA Lane 1984 Active metabolites of antidepressants: pharmacodynamics and relevant pharmacokinetics Adv Biochem Psychopharmacol 39 373 390 1:CAS:528:DyaL2cXkvVegurY%3D 6205563
63. SG Dahl 1982 Active metabolites of neuroleptic drugs: possible contribution to therapeutic and toxic effects Ther Drug Monit 4 33 40 1:CAS:528:DyaL38Xks1GktLk%3D 6122292
64. A Fura 2006 Role of pharmacologically active metabolites in drug discovery and development Drug Discov Today. 11 133 142 1:CAS:528: DC%2BD28Xit1Cktbk%3D 16533711
65. DA Smith RS Obach 2006 Metabolites and safety: what are the concerns, and how should we address them? Chem Res Toxicol 19 1570 1579 1:CAS:528: DC%2BD28XhtV2qs73L 17173370
66. SC Gad 2003 Active drug metabolites in drug development Curr Opin Pharmacol. 3 98 100 1:CAS:528:DC%2BD3sXmsVaqug%3D%3D 12550749
67. N Uemura T Onishi A Mitaniyama T Kaneko K Ninomiya K Nakamura M Tateno 2005 Bioequivalence and rapid absorption of zolmitriptan nasal spray compared with oral tablets in healthy Japanese subjects Clin Drug Invest. 25 199 208 1:CAS:528:DC%2BD2MXjtFamsr8%3D
68. R Yates K Nairn R Dixon E Seaber 2002 Preliminary studies of the pharmacokinetics and tolerability of zolmitriptan nasal spray in healthy volunteers J Clin Pharmacol. 42 1237 1243 1:CAS:528:DC%2BD38XovVClt7s%3D 12412822
69. G Qian-Ling J Hedner R Björkman T Hedner 1992 Morphine-3-glucuronide may functionally antagonize morphine-6-glucuronide induced antinociception and ventilatory depression in the rat Pain 48 249 255
70. MT Smith JA Watt T Cramond 1990 Morphine-3-glucuronide-a potent antagonist of morphine analgesia Life Sci 47 579 585 1:CAS:528: DyaK3cXltV2htro%3D 2402182
71. B Tuk MF Van Oostenbruggen VMM Herben JW Mandema M Danhof 1999 Characterization of the pharmacodynamic interaction between parent drug and active metabolite in vivo: midazolam and alpha-OH-midazolam J Pharmacol Exp Ther. 289 1067 1074 1:CAS:528:DyaK1MXislGisLc%3D 10215689
72. LJ Lesko AJ Atkinson Jr 2001 Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies Annu Rev Pharmacol Toxicol 41 347 366 1:CAS:528:DC%2BD3MXjsVaqtrs%3D 11264461
73. WR Lumry 1999 A review of the preclinical and clinical data of newer intranasal steroids used in the treatment of allergic rhinitis J Allergy Clin Immunol. 104 S150 S158 1:CAS:528:DyaK1MXnsFSmsrs%3D 10518812
74. SJ Szefler 2001 Pharmacokinetics of intranasal corticosteroids J Allergy Clin Immunol. 108 S26 S31 1:CAS:528:DC%2BD3MXmtVKhsrg%3D 11449203
75. BJ Lipworth JR Seckl 1997 Measures for detecting systemic bioactivity with inhaled and intranasal corticosteroids Thorax. 52 476 482 1:STN:280:DyaK2szhvFKguw%3D%3D 9176542
76. AM Wilson EJ Sims LC McFarlane BJ Lipworth 1998 Effects of intranasal corticosteroids on adrenal, bone, and blood markers of systemic activity in allergic rhinitis J Allergy Clin Immunol. 102 598 604 1:CAS:528: DyaK1cXntlWlsb8%3D 9802367
77. R Krishnamoorthy AK Mitra 1998 Prodrugs for nasal drug delivery Adv Drug Delivery Rev. 29 135 146 1:CAS:528:DyaK2sXnvFGgsbg%3D
78. JL Lewis KJ Nikula R Novak AR Dahl 1994 Comparative localization of carboxylesterase in F344 rat, beagle dog, and human nasal tissue Anat Rec 239 55 64 1:CAS:528:DyaK2cXltlSltrg%3D 8037378
79. B Pavan A Dalpiaz N Ciliberti C Biondi S Manfredlni S Vertuani 2008 Progress in drug delivery to the central nervous system by the prodrug approach Molecules 13 1035 1065 1:CAS:528:DC%2BD1cXlvFejsrY%3D 18560328
80. HD Kao A Traboulsi S Itoh L Dittert A Hussain 2000 Enhancement of the systemic and CNS specific delivery of L-dopa by the nasal administration of its water soluble prodrugs Pharm Res 17 978 984 1:CAS:528:DC%2BD3cXntVSltbk%3D 11028945
81. AM Al-Ghananeem AA Traboulsi LW Dittert AA Hussain 2002 Targeted brain delivery of 17beta-estradiol via nasally administered water soluble prodrugs AAPS PharmSciTech 3 40 47
82. TK Kim W Kang IK Chun SY Oh YH Lee HS Gwak 2009 Pharmacokinetic evaluation and modeling of formulated levodopa intranasal delivery systems Eur J Pharmaceut Sci. 38 525 532 1:CAS:528:DC%2BD1MXhsVKgsL3P
83. H Wang AA Hussain PJ Wedlund 2005 Nipecotic acid: systemic availability and brain delivery after nasal administration of nipecotic acid and n-butyl nipecotate to rats Pharm Res 22 556 562 1:CAS:528:DC%2BD2MXjsFagsrY%3D 15846463
84. T Yajima K Juni M Saneyoshi T Hasegawa T Kawaguchi 1998 Direct transport of 2′, 3′-didehydro-3′-deoxythymidine (D4T) and its ester derivatives to the cerebrospinal fluid via the nasal mucous membrane in rats Biol Pharm Bull 21 272 277 1:CAS:528:DyaK1cXit1Kmtbg%3D 9556159
85. UA Remigius M Jorissen T Willems R Kinget N Verbeke 2003 Mechanistic appraisal of the effects of some protease inhibitors on ciliary beat frequency in a sequential cell culture system of human nasal epithelium Eur J Pharm Biopharm 55 283 289 1:CAS:528:DC%2BD3sXjs1Gjt7s%3D 12754002
86. CH Huang R Kimura R Bawarshi-Nassar A Hussain 1985 Mechanism of nasal absorption of drugs. II. Absorption of L-tyrosine and the effect of structural modification on its absorption J Pharm Sci. 74 1298 1301 1:CAS:528: DyaL28XotFGhtA%3D%3D 4087196
87. A Hussain S Hamadi M Kagashima K Iseki L Dittert 1991 Does increasing the lipophilicity of peptides enhance their nasal absorption? J Pharm Sci. 80 1180 1181 1:CAS:528:DyaK38XmslSnsA%3D%3D 1815079
88. A Donnelly IW Kellaway SJ Farr G Taylor N Tudball M Gibson 1996 The influence of lipophilicity upon the nasal absorption of a series of hexapeptides Int J Pharm. 135 191 197 1:CAS:528:DyaK28XjsVOqsrY%3D
89. MA Hussain R Seetharam RR Wilk BJ Aungst CA Kettner 1995 Nasal mucosal metabolism and absorption of pentapeptide enkephalin analogs having varying n-terminal amino acids J Pharm Sci. 84 62 64 1:CAS:528:DyaK2MXis1Clsbo%3D 7714746
90. DH Na YS Youn EJ Park JM Lee OR Cho KR Lee SD Lee SD Yoo PP Deluca KC Lee 2004 Stability of PEGylated salmon calcitonin in nasal mucosa J Pharm Sci. 93 256 261 1:CAS:528:DC%2BD2cXhsFagurc%3D 14705183
91. BS Shin JH Jung KC Lee SD Yoo 2004 Nasal absorption and pharmacokinetic disposition of salmon calcitonin modified with low molecular weight polyethylene glycol Chem Pharm Bull 52 957 960 1:CAS:528:DC%2BD2cXmvVKkuro%3D 15304989
92. CS Fishburn 2008 The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics J Pharm Sci. 97 4167 4183 1:CAS:528: DC%2BD1cXht1Sgt7rI 18200508
93. T Prueksaritanont JH Lin TA Baillie 2006 Complicating factors in safety testing of drug metabolites: kinetic differences between generated and preformed metabolites Toxicol Appl Pharmacol 217 143 152 1:CAS:528:DC%2BD28Xht1SmsLbP 17055014
94. KS Pang ME Morris H Sun 2008 Formed and preformed metabolites: facts and comparisons J Pharm Pharmacol. 60 1247 1275 1:CAS:528:DC%2BD1cXhtlWiurvN 18812018
95. EF McCance LH Price TR Kosten PI Jatlow 1995 Cocaethylene: pharmacology, physiology and behavioral effects in humans J Pharmacol Exp Ther. 274 215 223 1:CAS:528:DyaK2MXntVWltro%3D 7616402
96. L Illum SS Davis M Pawula AN Fisher DA Barrett NF Farraj PN Shaw 1996 Nasal administration of morphine-6-glucuronide in sheep-a pharmacokinetic study Biopharm Drug Dispos 17 717 724 1:CAS:528:DyaK28XntFWitbc%3D 8950049
97. NN Vachharajani WC Shyu DS Greene RH Barbhaiya 1997 The pharmacokinetics of butorphanol and its metabolites at steady state following nasal administration in humans Biopharm Drug Dispos 18 191 202 1:CAS:528: DyaK2sXis1Kgs7Y%3D 9113342
98. RC Gaver M Vasiljev H Wong I Monkovic JE Swigor DR Van Harken RD Smyth 1980 Disposition of parenteral butorphanol in man Drug Metab Dispos 8 230 235 1:CAS:528:DyaL3cXlvFOnt70%3D 6105056
99. O Dale C Hoffer P Sheffels ED Kharasch 2002 Disposition of nasal, intravenous, and oral methadone in healthy volunteers Clin Pharmacol Ther 72 536 545 1:CAS:528:DC%2BD38XpsFSisLk%3D 12426517
100. A Takala V Kaasalainen T Seppala E Kalso KT Olkkola 1997 Pharmacokinetic comparison of intravenous and intranasal administration of oxycodone Acta Anaesthesiol Scand 41 309 312 1:STN:280:DyaK2s3hs1eluw%3D%3D 9062618
101. R Nave R Herzog A Laurent MA Wingertzahn 2009 Pharmacokinetics of ciclesonide and desisobutyryl ciclesonide after administration via aqueous nasal spray or hydrofluoroalkane nasal aerosol compared with orally inhaled ciclesonide: an open-label, single-dose, three-period crossover study in healthy volunteers Clin Ther 31 2988 2999 1:CAS:528:DC%2BC3cXhvVygu7c%3D 20110036
102. EJ Cone 1995 Pharmacokinetics and pharmacodynamics of cocaine J Anal Toxicol. 19 459 478 1:CAS:528:DyaK2MXosFSqurY%3D 8926741
103. JM Malinovsky F Servin A Cozian JY Lepage M Pinaud 1996 Ketamine and norketamine plasma concentrations after i.v., nasal and rectal administration in children Br J Anaesth 77 203 207 1:CAS:528:DyaK28Xltlagurw%3D 8881626
104. Y Yanagihara M Ohtani S Kariya K Uchino T Hiraishi N Ashizawa T Aoyama Y Yamamura Y Yamada T Iga 2003 Plasma concentration profiles of ketamine and norketamine after administration of various ketamine preparations to healthy Japanese volunteers Biopharm Drug Dispos 24 37 43 1:CAS:528: DC%2BD3sXnvV2ksw%3D%3D 12516077
105. PD Knoester DM Jonker RTM van der Hoeven TAC Vermeij PM Edelbroek GJ Brekelmans GJ de Haan 2002 Pharmacokinetics and pharmacodynamics of midazolam administered as a concentrated intranasal spray. A study in healthy volunteers Br J Clin Pharmacol 53 501 507 1:CAS:528:DC%2BD38Xks1Omsr4%3D 11994056
106. S Bjorkman G Rigemar J Idvall 1997 Pharmacokinetics of midazolam given as an intranasal spray to adult surgical patients Br J Anaesth 79 575 580 1:CAS:528:DyaK2sXnvFaiu7c%3D 9422893
107. RU Agu HV Dang M Jorissen R Kinget N Verbeke 2004 Metabolism and absorption enhancement of methionine enkephalin in human nasal epithelium Peptides (N Y, NY, U S ) 25 563 569 1:CAS:528:DC%2BD2cXksVCiurs%3D
108. MA Hussain CA Koval AB Shenvi BJ Aungst 1990 Recovery of rat nasal mucosa from the effects of aminopeptidase inhibitors J Pharm Sci. 79 398 400 1:CAS:528:DyaK3cXksFantbY%3D 2352157
109. RU Agu HV Dang M Jorissen T Willems R Kinget N Verbeke 2002 Nasal absorption enhancement strategies for therapeutic peptides: an in vitro study using cultured human nasal epithelium Int J Pharm. 237 179 191 1:CAS:528:DC%2BD38Xislyrtr8%3D 11955816
110. L Jorgensen E Bechgaard 1994 Intranasal permeation of thyrotropin-releasing hormone: in vitro study of permeation and enzymic degradation Int J Pharm. 107 231 237 1:CAS:528:DyaK2cXksValsrg%3D
111. T Kissel U Werner 1998 Nasal delivery of peptides: an in vitro cell culture model for the investigation of transport and metabolism in human nasal epithelium J Controlled Release. 53 195 203 1:CAS:528:DyaK1cXitVCjs7Y%3D
112. K Ohkubo JN Baraniuk RJ Hohman HC Kaulbach JN Hausfeld M Merida MA Kaliner 1993 Human nasal mucosal neutral endopeptidase (NEP): location, quantitation, and secretion Am J Respir Cell Mol Biol 9 557 567 1:CAS:528:DyaK2cXhsF2mtLs%3D 8217197
113. K Ohkubo CH Lee JN Baraniuk M Merida JN Hausfeld MA Kaliner 1994 Angiotensin-converting enzyme in the human nasal mucosa Am J Respir Cell Mol Biol 11 173 180 1:CAS:528:DyaK2cXmvFOmurg%3D 8049077
114. K Ohkubo JN Baraniuk M Merida JN Hausfeld H Okada MA Kaliner 1995 Human nasal mucosal carboxypeptidase: activity, location, and release J Allergy Clin Immunol. 96 924 931 1:CAS:528:DyaK28Xht1ChtL4%3D 8543751
115. RU Agu DU Obimah WJ Lyzenga M Jorissen E Massoud N Verbeke 2009 Specific aminopeptidases of excised human nasal epithelium and primary culture: a comparison of functional characteristics and gene transcripts expression J Pharm Pharmacol. 61 599 606 1:CAS:528:DC%2BC3cXmtVemsA%3D%3D 19405998
116. Peter H. Cell culture sheets to study nasal peptide metabolism:the human nasal RPMI 2650 cell line model. Thesis, Swiss Federal Institute of Technology Zurich (ETH), Switzerland, 1996.
117. A Hussain J Faraj Y Aramaki JE Truelove 1985 Hydrolysis of leucine enkephalin in the nasal cavity of the rat-a possible factor in the bioavailability of nasally administered peptides Biochem Biophys Res Commun 133 923 928 1:CAS:528:DyaL28Xmt1Cruw%3D%3D 4084310
118. U Werner T Kissel 1995 Development of a human nasal epithelial cell culture model and its suitability for transport and metabolism studies under in vitro conditions Pharm Res 12 565 571 1:CAS:528:DyaK2MXltFaqt74%3D 7596993
119. MC Schmidt D Simmen M Hilbe P Boderke G Ditzinger J Sandow S Lang W Rubas HP Merkle 2000 Validation of excised bovine nasal mucosa as in vitro model to study drug transport and metabolic pathways in nasal epithelium J Pharm Sci. 89 396 407 1:CAS:528:DC%2BD3cXit1KntLo%3D 10707019
120. L Joergensen E Bechgaard 1993 Intranasal absorption of angiopeptin: in vitro study of absorption and enzymic degradation Int J Pharm. 99 165 172 1:CAS:528:DyaK2cXhsVOmtw%3D%3D
121. S Gizurarson E Bechgaard 1991 Study of nasal enzyme activity towards insulin. In vitro Chem Pharm Bull 39 2155 2157 1:CAS:528:DyaK3MXmt1ChsL4%3D 1797441
122. AA Hussain K Iseki M Kagoshima LW Dittert 1990 Hydrolysis of peptides in the nasal cavity of humans J Pharm Sci. 79 947 948 1:CAS:528: DyaK3MXnsVKgsQ%3D%3D 2280369
123. UE Westin E Bostroem J Grasjoe M Hammarlund-Udenaes E Bjoerk 2006 Direct nose-to-brain transfer of morphine after nasal administration to rats Pharm Res 23 565 572 1:CAS:528:DC%2BD28Xitlemtb0%3D 16489488
124. H Ghantous L Dencker J Gabrielsson BRG Danielsson K Bergman 1990 Accumulation and turnover of metabolites of toluene and xylene in nasal mucosa and olfactory bulb in the mouse Pharmacol Toxicol 66 87 92 1:CAS:528: DyaK3cXhsFegsrg%3D 2315269
125. KV Shevchenko IY Nagaev LY Alfeeva LA Andreeva AA Kamenskii NG Levitskaya VP Shevchenko IA Grivennikova NF Myasoedov 2006 Kinetics of semax penetration into the brain and blood of rats after its intranasal administration Russ J Bioorg Chem. 32 57 62 1:CAS:528:DC%2BD28XitVamsL4%3D